Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
740 stopped studies mapped to Myeloproliferative Neoplasm and descendants · 88% state a reason
Over the 740 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT02181699 | Study of KHK2823 in Patients With Acute Myeloid Leukemia (AML) and Myelodysplastic… | Phase 1 | terminated | Jul 4, 2014 | Kyowa Kirin, Inc. | Failed treatment response | Other (stated, no rule matched) |
| NCT05895201 | High-Dose Post-Transplant Cyclophosphamide, Bortezomib, and Sitagliptin for the… | Phase 1 / Phase 2 | withdrawn | Jun 8, 2023 | Indiana University | PI has left IU with no plan to initiate study at IU | Other (stated, no rule matched) |
| NCT00779480 | Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Study of KW-2449 in Acute… | Phase 1 | terminated | Oct 24, 2008 | Kyowa Kirin Co., Ltd. | Failure to demonstrate a tolerable dose that had potential for efficacy. | Efficacy / futility |
| NCT05524857 | Combination of Fedratinib and Decitabine for Myeloproliferative Neoplasms (MPN)-… | Phase 1 | terminated | Sep 1, 2022 | Joseph Jurcic | Closed by Sponsor | Other (stated, no rule matched) |
| NCT04571645 | Dociparstat in Combination With Standard Chemotherapy for the Treatment of Acute Myeloid…(AML) | Phase 3 | terminated | Oct 1, 2020 | Jazz Pharmaceuticals | Study enrollment was terminated on 16 May 2022 due to slow recruitment. | Enrollment / accrual |
| NCT06362031 | A Study to Explore Treatment Patterns, Treatment Outcomes, Healthcare Resource… | — | withdrawn | Apr 12, 2024 | AbbVie | Strategic considerations | Sponsor / business decision |
| NCT05367401 | A Study of Sabatolimab and Magrolimab-based Treatment in AML or Higher Risk MDS… | Phase 1 / Phase 2 | withdrawn | May 10, 2022 | Novartis Pharmaceuticals | waiting for update from Study Lead | Other (stated, no rule matched) |
| NCT02455024 | An Observational Registry to Evaluate the Incidence of and Risk Factors for Vascular…(OMNI) | — | terminated | May 27, 2015 | Ariad Pharmaceuticals | Business Decision; Insufficient Enrollment | Enrollment / accrual |
| NCT02446145 | A Randomized Placebo-controlled Phase 2 Study of Decitabine With or Without Eltrombopag…(DELTA) | Phase 2 | terminated | May 18, 2015 | Technische Universität Dresden | Due to COVID-19 pandemia, recruitment was insufficient to reach required sample size in an… | COVID-19 / pandemic |
| NCT04113616 | An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 When… | Phase 1 / Phase 2 | terminated | Oct 3, 2019 | Kartos Therapeutics, Inc. | In September 2023, the study was terminated because of a Sponsor decision, unrelated to safety… | Safety / toxicity |
| NCT04793399 | Safety and Efficacy Evaluation of Bosutinib Plus Atezolizumab in Newly Diagnosed Chronic… | Phase 1 / Phase 2 | terminated | Mar 11, 2021 | Fundacion Espanola para la Curacion de la Leucemia Mieloide Cronica | The study has been prematurely terminated due to the onset of 2 dose limiting toxicities in 2… | Safety / toxicity |
| NCT02734823 | Long Term Effects of Tyrosine Kinase Inhibitor Therapy on Ovarian Reserve and Fertility… | — | withdrawn | Apr 12, 2016 | University of Southern California | Lack of accrual | Enrollment / accrual |
| NCT05720988 | Tagraxofusp to Eradicate Measurable Residual Disease in Patients With Acute Myeloid… | Phase 1 | withdrawn | Feb 9, 2023 | Jonsson Comprehensive Cancer Center | trial was not opened | Other (stated, no rule matched) |
| NCT03878524 | Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME… | Phase 1 | terminated | Mar 18, 2019 | OHSU Knight Cancer Institute | Low accrual | Enrollment / accrual |
| NCT04912063 | Study to Evaluate Adverse Events and Movement of Lemzoparlimab in Body When Used… | Phase 1 | terminated | Jun 3, 2021 | AbbVie | Strategic considerations | Sponsor / business decision |
| NCT05345938 | A Study of Mitoxantrone Hydrochloride Liposome Injection in Subjects With Acute Myeloid… | Phase 1 / Phase 2 | terminated | Apr 26, 2022 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Adjust the research strategy. | Sponsor / business decision |
| NCT02508324 | IPA Targeted Adoptive Immunotherapy vs Adult Haplo-identical Cell Infusion During… | Phase 2 | terminated | Jul 24, 2015 | Weill Medical College of Cornell University | Slow accrual and change in direction of cord blood program | Enrollment / accrual |
| NCT04956042 | Study of Fosciclopirox in Patients With Relapsed/Refractory Acute Myeloid Leukemia | Phase 1 / Phase 2 | terminated | Jul 9, 2021 | CicloMed LLC | Discontinued | Other (stated, no rule matched) |
| NCT05829434 | Magrolimab Plus Intensive Chemotherapy in Newly Diagnosed AML or HR-MDS(MAGROLIC) | Phase 2 | withdrawn | Apr 25, 2023 | Uwe Platzbecker | Trial was stopped prematurely due to safety reasons | Safety / toxicity |
| NCT05107856 | PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or… | Phase 1 | terminated | Nov 4, 2021 | Prelude Therapeutics | Company Decision | Sponsor / business decision |
| NCT02152956 | Flotetuzumab in Primary Induction Failure (PIF) or Early Relapse (ER) Acute Myeloid…(VOYAGE) | Phase 1 / Phase 2 | terminated | Jun 2, 2014 | MacroGenics | Business decision | Sponsor / business decision |
| NCT04092179 | Study of Enasidenib and Venetoclax in IDH2-Mutated Blood Cancers | Phase 1 / Phase 2 | terminated | Sep 17, 2019 | University Health Network, Toronto | Insufficient Funding | Funding |
| NCT04996030 | A Study for Oral SY-2101 for Participants With Acute Promyelocytic Leukemia | Phase 1 | suspended | Aug 9, 2021 | Syros Pharmaceuticals | Prioritization | Other (stated, no rule matched) |
| NCT03972943 | CPAP in Treating Obstructive Sleep Apnea in Patients With Polycythemia Vera or Essential… | Early Phase 1 | terminated | Jun 4, 2019 | University of Utah | Study terminated due to lack of funding | Funding |
| NCT04196010 | Continuous Infusion Chemotherapy (CI-CLAM) for the Treatment of Relapsed or Refractory… | Phase 1 | terminated | Dec 12, 2019 | University of Washington | Terminated due to unfavorable risk-benefit ratio of investigational regimen. | Other (stated, no rule matched) |
| NCT05066165 | Study Investigating NTLA-5001 in Subjects With Acute Myeloid Leukemia | Phase 1 / Phase 2 | terminated | Oct 4, 2021 | Intellia Therapeutics | Pivoting to an allogeneic version of this program currently in preclinical development. | Other (stated, no rule matched) |
| NCT06180863 | Oral Azacitidine (CC-486) Epigenetic Priming and Maintenance for Adult Acute Myeloid… | Phase 2 | withdrawn | Dec 26, 2023 | Yale University | Lack of funding. | Funding |
| NCT05201183 | A Dose Escalation Study of Intensity Modulated Total Marrow Irradiation (IMRT-TMI)… | Phase 1 / Phase 2 | withdrawn | Jan 21, 2022 | Naoyuki G. Saito, M.D., Ph.D. | insufficient staff and updates in standard practice have made it difficult to recruit participants | Enrollment / accrual |
| NCT05321940 | Safety Trial of STING-dependent Activators and Stimulated Dendritic Cells for Aggressive… | Phase 1 | withdrawn | Apr 11, 2022 | Juan C. Ramos, MD | Investigator decision | Investigator |
| NCT00540995 | Busulfan, Etoposide, and Intensity-Modulated Radiation Therapy Followed By Donor Stem… | Phase 1 / Phase 2 | terminated | Oct 8, 2007 | City of Hope Medical Center | Unable to safely escalate to TMLI doses that were hypothesized to be effective and less toxic than… | Enrollment / accrual |
| NCT03904251 | CPX-351 and Gemtuzumab Ozogamicin in Treating Patients With Relapsed Acute Myeloid… | Phase 1 | terminated | Apr 5, 2019 | Jonsson Comprehensive Cancer Center | slow accrual | Enrollment / accrual |
| NCT02520011 | Alvocidib Biomarker-driven Phase 2 AML Study | Phase 2 | terminated | Aug 11, 2015 | Sumitomo Pharma America, Inc. | Due to slow enrollment, the extensive time projected to conclude the study hypothesis rendered the… | Enrollment / accrual |
| NCT03969420 | Study of Alvocidib in Patients With Relapsed/Refractory AML Following Treatment With… | Phase 2 | terminated | May 31, 2019 | Sumitomo Pharma America, Inc. | Business decision to terminate the development of alvocidib program on 17 November 2020. Patients… | Sponsor / business decision |
| NCT05943314 | Clinical Study on Safety and Efficacy of Anti-CLL1 /+CD33 CAR T Cells in the Treatment of… | N/A | withdrawn | Jul 13, 2023 | Guangzhou Bio-gene Technology Co., Ltd | The clinical trial was terminated due to a change in sponsor strategy. | Sponsor / business decision |
| NCT04023071 | FT516 in Subjects With Advanced Hematologic Malignancies | Phase 1 | terminated | Jul 17, 2019 | Fate Therapeutics | The study was terminated by the Sponsor. | Other (stated, no rule matched) |
| NCT04485052 | Efficacy and Safety Evaluation of IBI188 in Combination With Demethylating Agents in… | Phase 1 / Phase 2 | suspended | Jul 24, 2020 | Innovent Biologics (Suzhou) Co. Ltd. | Pause for changes in development strategies | Sponsor / business decision |
| NCT03690154 | A Phase 1 Study to Evaluate FN-1501 Monotherapy in Patients With Advanced Solid Tumors… | Phase 1 | terminated | Oct 1, 2018 | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | Despite demonstrated safety and tolerability the trial was terminated early due to program… | Safety / toxicity |
| NCT04629651 | Captopril Use on the Degree of Marrow Fibrosis in Bone Marrow Fibrosis/Myeloproliferative… | Phase 1 / Phase 2 | withdrawn | Nov 16, 2020 | Case Comprehensive Cancer Center | PI discretion | Other (stated, no rule matched) |
| NCT02957032 | A Study of the Tumor-targeting Human F16IL2 Monoclonal Antibody-cytokine Fusion Protein… | Phase 1 | terminated | Nov 7, 2016 | Philogen S.p.A. | New agents for the same indication impacted on patients' recruitment | Enrollment / accrual |
| NCT02743611 | Safety & Activity of Controllable PRAME-TCR Therapy in Previously Treated AML/MDS or… | Phase 1 / Phase 2 | terminated | Apr 19, 2016 | Bellicum Pharmaceuticals | company decision | Sponsor / business decision |
| NCT04166929 | Haploidentical Stem Cell Transplant With or Without NK Cell Infusion in AML and MDS(Bigeminy) | Phase 2 | terminated | Nov 18, 2019 | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | low recruitment | Enrollment / accrual |
| NCT05456269 | A Study of Bisantrene Combined With Cytarabine or With Decitabine for Adult Subjects With…(BISECT) | Phase 1 | withdrawn | Jul 13, 2022 | Racura Oncology Ltd | commercial reason | Other (stated, no rule matched) |
| NCT03699475 | Study of Haplo-HSCT + Rivogenlecleucel vs Haplo-HSCT + Post Transplant Cyclophosphamide…(THRIVE) | Phase 2 / Phase 3 | terminated | Oct 9, 2018 | Bellicum Pharmaceuticals | Funding, portfolio re-prioritization | Funding |
| NCT03067571 | Daratumumab in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or… | Phase 2 | terminated | Mar 1, 2017 | M.D. Anderson Cancer Center | Study terminated early because of lack of efficacy | Efficacy / futility |
| NCT04614636 | FT538 in Subjects With Advanced Hematologic Malignancies | Phase 1 | terminated | Nov 4, 2020 | Fate Therapeutics | This study was terminated by the Sponsor. | Other (stated, no rule matched) |
| NCT05144334 | A Study of BTX-1188 in Subjects With Advanced Malignancies | Phase 1 | terminated | Dec 3, 2021 | Biotheryx, Inc. | Business decision | Sponsor / business decision |
| NCT04002115 | Clofarabine Pre-conditioning Followed by Stem Cell Transplant for Non-remission AML | Phase 2 | terminated | Jun 28, 2019 | Milton S. Hershey Medical Center | terminated due to low accrual | Enrollment / accrual |
| NCT04079738 | Study Augmenting TAK-659 Action in Relapsed/Refractory AML by Addition Ofthe Proteasome… | Phase 1 / Phase 2 | terminated | Sep 6, 2019 | H Scott Boswell | Funder requested termination due to halting internal development of TAK-659 | Other (stated, no rule matched) |
| NCT01044745 | Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant… | Phase 2 | terminated | Jan 8, 2010 | University of Nebraska | Study was closed to accrual for safety related to the frequency of BK infections. | Safety / toxicity |
| NCT03224819 | Study of Emerfetamab (AMG 673) in Adults With Relapsed/Refractory Acute Myeloid Leukemia… | Early Phase 1 | terminated | Jul 21, 2017 | Amgen | Priortization of other Programs | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Apr 29, 2024source: clinicaltrials